Back to top
more

uniQure (QURE)

(Delayed Data from NSDQ)

$49.56 USD

49.56
778,405

-1.39 (-2.73%)

Updated Aug 27, 2026 04:00 PM ET

After-Market: $49.55 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (158 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Ekta Bagri headshot

Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback

by Ekta Bagri

Acquisition and pipeline updates from Bristol Myers (BMY) and Akero Therapeutics (AKRO) are in focus in the biotech sector.

Zacks Equity Research

uniQure (QURE) Up on Restructuring Plans, Workforce Reduction

by Zacks Equity Research

uniQure (QURE) gains on plans to discontinue investment in some projects and reduce 20% of its workforce.

Zacks Equity Research

UniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of -148.48% and 98.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

FDA Accepts Pfizer's (PFE) Hemophilia B Gene Therapy Filing

by Zacks Equity Research

A final decision on Pfizer's (PFE) BLA filing, seeking approval for hemophilia B gene therapy, treatment is expected by second-quarter 2024.

Zacks Equity Research

uniQure (QURE) Falls on Mixed Huntington's Disease Study Results

by Zacks Equity Research

uniQure (QURE) stock declines after the company announces mixed results from its biomarkers analysis in the early-to-mid-stage study of AMT-130 in Huntington's disease.

Zacks Equity Research

Pfizer (PFE) Posts Upbeat Data From Hemophilia Drug Study

by Zacks Equity Research

Data from a late-stage study shows that treatment with Pfizer's (PFE) experimental anti-TFPI inhibitor led to a significant reduction in annualized bleeding rate in hemophilia A and B patients.

Zacks Equity Research

UniQure (QURE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of -59.80% and 79.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Options Traders Betting on a Big Move in UniQure (QURE) Stock?

by Zacks Equity Research

Investors need to pay close attention to UniQure (QURE) stock based on the movements in the options market lately.

Zacks Equity Research

UniQure (QURE) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of 128.85% and 85.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pfizer's (PFE) Hemophilia B Gene Therapy Meets Study Goal

by Zacks Equity Research

Data from a late-stage study shows that treatment with Pfizer's (PFE) hemophilia B gene therapy resulted in a 71% reduction in annualized bleed rate (ABR) compared to standard-of-care treatment.